Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2014 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2014 Financial Results

Ocular Therapeutix (OCUL) Price Target Raised to $50 at RBC

March 10, 2015 3:59 PM EDT

RBC Capital maintained an Outperform rating on Ocular Therapeutix (NASDAQ: OCUL) and raised its price target to $50.00 (from $35.00).

Analyst Adnan Butt said, "OCULs platform technology is already paying off with: (1) One positive Phase III reading out, (2) 5 clinical programs (2 Phase IIIs and 2 Phase IIs), (3) Pipeline surprises... More

Ocular Therapeutix (OCUL) Tops Q4 EPS by 1c

March 10, 2015 6:46 AM EDT

Ocular Therapeutix (NASDAQ: OCUL) reported Q4 EPS of ($0.37), $0.01 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $505 thousand versus the consensus estimate of $200 thousand.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.

... More